ArticleClinical journal of the American Society of Nephrology : CJASN2022
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03036150 (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease), which is not on this map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Chronic Kidney Disease (CKD): Systematic Review of the Cost Effectiveness of SGLT2 Inhibitors and Other Novel Nephroprotective Drugs.PharmacoEconomics · 2026Pooled it
- Application of SGLT2 inhibitors in kidney diseases: a bibliometric analysis.Frontiers in medicine · 2026Pooled it
- Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review.BMC nephrology · 2024Pooled it
- Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2024Pooled it
- The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Trial
- Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.Annals of internal medicine · 2023Trial
- Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Trial
- Article
- A systematic review of the cost-utility of dapagliflozin for managing chronic kidney disease.Cost effectiveness and resource allocation : C/E · 2026Review
- Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.Kidney international reports · 2026Review
- Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings.Kidney medicine · 2026Article
- Cost-utility analysis of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression in patients with type 2 diabetes mellitus.BMC nephrology · 2026Article
- 10 tips on performing economic evaluation in kidney disease.Clinical kidney journal · 2026Review
- SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications.Drugs in context · 2026Review
- Dapagliflozin attenuates diabetic renal fibrosis by inhibiting macrophage-myofibroblast transitionPeerJ · 2026Article
- Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies.PharmacoEconomics · 2026Article
- Article
- CKD Prevalence and Associated Factors in Jamaica.Kidney international reports · 2025Article
- Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD.Kidney international reports · 2025Article
- Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease.EClinicalMedicine · 2025Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesCKD imposes a significant burden on patients and health care providers, particularly upon reaching kidney failure when patients may require KRT. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial demonstrated that dapagliflozin, with standard therapy, reduced CKD progression and KRT requirement. The study objective was to estimate the cost-effectiveness of dapagliflozin for the treatment of CKD from payer perspectives in the United Kingdom, Germany, and Spain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We constructed a lifetime Markov model to characterize outcomes in patients with CKD on the basis of the DAPA-CKD trial. Health states were defined by eGFR level and KRT type. Direct health care costs and utility values were sourced from published literature and the DAPA-CKD trial, respectively. Costs and benefits were discounted at 3.5% per annum in the United Kingdom and 3% in Germany and Spain.
resultsIn patients eligible for the DAPA-CKD trial, treatment with dapagliflozin was predicted to reduce rates of CKD progression, with patients predicted to spend 1.7 (95% credibility interval, 0.8 to 2.4) more years in the eGFR range 15-89 ml/min per 1.73 m
conclusionsIn patients meeting the eligibility requirements for the DAPA-CKD trial, dapagliflozin is likely to be a cost-effective treatment within the UK, German, and Spanish health care systems. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD), NCT03036150.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.